Progenics Pharmaceuticals, Inc. (PGNX) Misses Q4 EPS by 3c; Founder Maddon to Retire
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Price: $4.10 --0%
Financial Fact:
Operating income (loss): 36.2M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Operating income (loss): 36.2M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) reported Q4 EPS of ($0.32), $0.03 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $7.37 million.
The company also announced that company founder Paul J. Maddon, M.D., Ph.D. has retired as chief science officer of the company. He continues as a member and vice chair of the Progenics board of directors.
For earnings history and earnings-related data on Progenics Pharmaceuticals, Inc. (PGNX) click here.
The company also announced that company founder Paul J. Maddon, M.D., Ph.D. has retired as chief science officer of the company. He continues as a member and vice chair of the Progenics board of directors.
For earnings history and earnings-related data on Progenics Pharmaceuticals, Inc. (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- The LGL Group (LGL) Misses Q2 EPS by 8c
- OLB Group narrows net loss 50% as revenue falls in Q2 2026
Create E-mail Alert Related Categories
Earnings, Management ChangesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
